Hikma Pharmaceuticals Plc Audit Tender (5565Z)
September 18 2015 - 9:40AM
UK Regulatory
TIDMHIK
RNS Number : 5565Z
Hikma Pharmaceuticals Plc
18 September 2015
Hikma Pharmaceuticals PLC
Audit Tender Process
LONDON, 18 September 2015 - Hikma Pharmaceuticals PLC (the
"Company") announces that, following a formal tender process for
its statutory audit contract, which was initiated in line with
current corporate governance best practice, the Board have approved
the proposed appointment of PricewaterhouseCoopers LLP as the
Company's new statutory auditors, subject to approval by
shareholders at the 2016 AGM. Deloitte LLP will therefore stand
down as the Company's auditors at the conclusion of the 2016
AGM.
Pat Butler, Chairman of the Audit Committee, said: "On behalf of
the Board, I would like to thank Deloitte LLP for their significant
contribution to Hikma since listing in 2005 and before that as a
private company."
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2670
Susan Ringdal
VP, Corporate Strategy and Investor
Relations +44 20 7399 2670
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2014, Hikma achieved
revenues of $1,489 million and profit attributable to shareholders
of $278 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPKFDNNBKDFCD
(END) Dow Jones Newswires
September 18, 2015 09:40 ET (13:40 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024